Bosutinib effective and well tolerated in newly diagnosed CP-CML Presented ByProf. Tim Brümmendorf, RWTH Aachen University, Germany TrialPhase 3, BFORE ConferenceASH 2020 TypePeer-reviewed article 18 February 2021 09:17